Can Bellerophon Therapeutics Inc (NASDAQ:BLPH)’s Tomorrow be Different? The Stock Had Increase in Shorts

May 18, 2018 - By Samual Williams

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Logo

The stock of Bellerophon Therapeutics Inc (NASDAQ:BLPH) registered an increase of 13.34% in short interest. BLPH’s total short interest was 2.34M shares in May as published by FINRA. Its up 13.34% from 2.06M shares, reported previously. With 147,200 shares average volume, it will take short sellers 16 days to cover their BLPH’s short positions. The short interest to Bellerophon Therapeutics Inc’s float is 12.26%.

The stock increased 5.19% or $0.12 during the last trading session, reaching $2.43. About 478,282 shares traded or 203.05% up from the average. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 58.74% since May 18, 2017 and is uptrending. It has outperformed by 47.19% the S&P500.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $139.41 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

More news for Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) were recently published by: Streetinsider.com, which released: “Bellerophon Therapeutics (BLPH) Reports Agreement with FDA on Study Design of Phase 2b Trial of INOpulse for …” on May 08, 2018. Nasdaq.com‘s article titled: “Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension …” and published on May 16, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: